ALNYLAM PHARMACEUTICALS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2020-06-30 was $99.50M, a 74.53% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2019-06-30 was $390.58M.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2019-03-31 was $381.90M.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2020 was $99.50M, a 87.12% decline from fiscal 2019.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2019 was $772.48M.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2017 was $1.14B.
- ALNYLAM PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2015 was $496.40M, a 35.91% decline from fiscal 2014.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2020-12-31 | $99.50M 10-K · filed 2022-02-10 | |
| 2020-06-30 | $99.50M 10-Q · filed 2021-10-28 | |
| 2019-12-31 | $772.48M 10-K · filed 2022-02-10 | |
| 2019-06-30 | $390.58M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $381.90M 10-Q · filed 2020-11-05 | |
| 2017-12-31 | $1.14B 10-K · filed 2020-02-13 | |
| 2015-12-31 | $496.40M 10-K · filed 2018-02-15 | |
| 2014-12-31 | $774.49M 10-K · filed 2015-02-13 | |
| 2013-12-31 | $173.57M 10-K · filed 2016-02-12 | |
| 2012-12-31 | $86.80M 10-K · filed 2015-02-13 | |
| 2011-12-31 | $1.02M 10-K · filed 2012-02-13 | |
| 2010-12-31 | $2.42M 10-K · filed 2012-02-13 | |
| 2009-12-31 | $2.51M 10-K · filed 2012-02-13 | |
| 2008-12-31 | $6.51M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |